1-4 of 4
Scott Portwood, MS, MBA
Close
Sort by
Journal Articles

Combining IMGN779, a Novel Anti-CD33 Antibody-Drug Conjugate (ADC), with the PARP Inhibitor, Olaparib, Results in Enhanced Anti-Tumor Activity in Preclinical Acute Myeloid Leukemia (AML) Models

Scott Portwood, MS, MBA, Robert A Puchalski, Russell M Walker, MS, Eunice S. Wang, MD
Journal: Blood
Blood (2016) 128 (22): 1645.
https://doi.org/10.1182/blood.V128.22.1645.1645
Published: 2016
Journal Articles

Targeting Innate and Adaptive Immune Responses for the Treatment of Acute Myeloid Leukemia

Amanda Przespolewski, DO, Scott Portwood, MS, MBA, Jason Den Haese, MS, Demi Lewis, Eunice S. Wang, MD
Journal: Blood
Blood (2016) 128 (22): 2833.
https://doi.org/10.1182/blood.V128.22.2833.2833
Published: 2016
Journal Articles

Functional Genomics and Computational Approaches Identify Novel Small Molecules Targeting Quiescent Leukemia Stem Cells

Costakis Frangou, PhD, Jason Den Haese, PhD, Jordan Warunek, Scott Portwood, MS, MBA, Norma J Nowak, PhD, Andrei V Gudkov, PhD, Katerina Gurova, PhD, Meir Wetzler, MD, Eunice S. Wang, MD
Journal: Blood
Blood (2015) 126 (23): 1391.
https://doi.org/10.1182/blood.V126.23.1391.1391
Published: 2015
Journal Articles

Optimizing Effects of mTOR Inhibition in Acute Myelogenous Leukemia

Joshua Acklin, Mitra Azadniv, PhD, Scott Portwood, MS, MBA, Kimberly Lacagnina, MA, Charlotte Beers, Eunice S. Wang, MD, Jane L. Liesveld, MD
Journal: Blood
Blood (2015) 126 (23): 4930.
https://doi.org/10.1182/blood.V126.23.4930.4930
Published: 2015